1. Home
  2. SAGE vs EAD Comparison

SAGE vs EAD Comparison

Compare SAGE & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • EAD
  • Stock Information
  • Founded
  • SAGE 2010
  • EAD 2003
  • Country
  • SAGE United States
  • EAD United States
  • Employees
  • SAGE N/A
  • EAD N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • EAD Finance/Investors Services
  • Sector
  • SAGE Health Care
  • EAD Finance
  • Exchange
  • SAGE Nasdaq
  • EAD Nasdaq
  • Market Cap
  • SAGE 413.9M
  • EAD 400.1M
  • IPO Year
  • SAGE 2014
  • EAD N/A
  • Fundamental
  • Price
  • SAGE $6.46
  • EAD $6.84
  • Analyst Decision
  • SAGE Hold
  • EAD
  • Analyst Count
  • SAGE 19
  • EAD 0
  • Target Price
  • SAGE $9.88
  • EAD N/A
  • AVG Volume (30 Days)
  • SAGE 815.0K
  • EAD 178.9K
  • Earning Date
  • SAGE 04-29-2025
  • EAD 01-01-0001
  • Dividend Yield
  • SAGE N/A
  • EAD 8.91%
  • EPS Growth
  • SAGE N/A
  • EAD N/A
  • EPS
  • SAGE N/A
  • EAD N/A
  • Revenue
  • SAGE $47,404,000.00
  • EAD N/A
  • Revenue This Year
  • SAGE $103.73
  • EAD N/A
  • Revenue Next Year
  • SAGE $41.15
  • EAD N/A
  • P/E Ratio
  • SAGE N/A
  • EAD N/A
  • Revenue Growth
  • SAGE N/A
  • EAD N/A
  • 52 Week Low
  • SAGE $4.62
  • EAD $5.69
  • 52 Week High
  • SAGE $13.47
  • EAD $6.81
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 38.73
  • EAD 61.58
  • Support Level
  • SAGE $6.36
  • EAD $6.68
  • Resistance Level
  • SAGE $6.78
  • EAD $6.84
  • Average True Range (ATR)
  • SAGE 0.24
  • EAD 0.06
  • MACD
  • SAGE -0.01
  • EAD 0.00
  • Stochastic Oscillator
  • SAGE 12.22
  • EAD 100.00

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

Share on Social Networks: